Gilead China test leaked......Gilead Sciences shares were lower on Thursday after a potential antiviral drug for the coronavirus failed its first randomized clinical trial, a report said. a sign in front of a building: Gilead Sciences Falls on Draft Report of Failed Coronavirus Drug Test TheStreetGilead Sciences Falls on Draft Report of Failed Coronavirus Drug Test The Chinese trial showed remdesivir, which was developed by the Foster City, Calif., biopharma, did not improve patients' condition or reduce the pathogen's presence in the bloodstream, according to the Financial Times, which cited draft documents published accidentally by the World Health Organization. "In this study of hospitalized adult patients with severe COVID-19 that was terminated prematurely, remdesivir was not associated with clinical or virological benefits," the summary stated. Gilead warned that the post included "inappropriate characterizations of the study." WHO spokesperson Tarik Jasarevic said that "a draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed." "The manuscript is undergoing peer review and we are waiting for a final version before WHO comments," Jasarevic said, according to CNBC. Earlier this month, Chinese authorities had halted two trials for remdesivir, saying that there weren't enough patients to fully enroll the studies. "We regret that the WHO prematurely posted information regarding the study, which has since been removed," Gilead said in a statement. "The investigators in this study did not provide permission for publication of results. Furthermore, we believe the post included inappropriate characterizations of the study. Importantly, because this study was terminated early due to low enrollment, it was underpowered to enable statistically meaningful conclusions." As such, the statement continued, "the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease. We understand the available data have been submitted for peer-reviewed publication, which will provide more detailed information from this study in the near future." Gilead Sciences shares rose last week after a specialist medical website said the drugmaker's coronavirus treatment was inducing rapid recoveries from patients suffering severe symptoms of the deadly disease. At last check, Gilead shares were off 2.8% at $79.03.